This paper reports clinical and cytogenetic data from 125 cases with t(9;11)(p21-22;q32) which were accepted for a European Union Concerted Action Workshop on 11q23. This chromosome abnormality is known to occur predominantly in acute myeloid leukemia (AML) FAB type M5a and less often in AML M4; in this series it was also found to occur, uncommonly, in other AML FAB types, in childhood acute lymphoblastic leukemia (ALL) (nine cases), in relatively young patients with myelodysplastic syndrome (MDS) (five cases), acute biphenotypic leukemia (two cases), and acute undifferentiated leukemia (one case). All age groups were represented but 50% of the patients were aged less than 15 years. The t(9;11) was the sole abnormality in 57 cases with AML; trisomy 8 was the most common additional abnormality (23 cases, including seven with further abnormalities), and 28 cases had other additional abnormalities. Among the t(9;11)+ve patients with AML, the white cell count (WBC) and age group were significant predictors of event-free survival; central nervous system (CNS) involvement or karyotype class (sole, with trisomy 8, or with other), also contributed to prognosis although our data could not show these to be independent factors. The best outcome was for patients aged 1-9 years, with low WBC, and with absence of CNS disease or presence of trisomy 8. For patients aged less than 15 years, the event-free survival for ALL patients was not significantly worse than that of AML patients.
Introduction
The t(9;11)(p21-22;q23) identifies the second largest group of translocations which involve 11q23 as an acquired abnormality in hemopoietic malignancies. 1 However, rather few previous publications have been specifically devoted to series of patients with this abnormality; [2] [3] [4] there have been some single case reports, [5] [6] [7] or else cases with t(9;11) have been reported in series which included cases with other abnormalities of 11q23, 8 which can result in a loss of clarity about the distinctive clinical features associated with this abnormality. The net morphological change produced by the t(9;11) is subtle, particularly of the 9p, so in practice this translocation may be underdetected if the chromosome morphology is poor. Fluorescence in situ hybridization (FISH) may be desirable to confirm that the 9 is the partner chromosome, and not some other which may be associated with quite different clinical features and outcome to treatment. t(9;11) is most often associated with acute myeloid leukemia (AML), usually those FAB types which have a substantial monocytic element, M4 and M5, but particularly M5a. In this particular FAB subtype it is the most commonly seen cytoCorrespondence: J Swansbury, Academic Haematology and Cytogenetics, Block F, The Royal Marsden NHS Trust, Sutton, Surrey, SM2 5PT, UK; Fax: 0181 770 7893 Received 10 October 1997; accepted 20 January 1998 genetic abnormality. At the molecular level, the typical rearrangement is between MLL (also known as ALL1, Htrx, HRX) at 11q23, and a gene known as AF9, MLLT3 or LTG9 at 9p21-22. 9 At this Workshop, clinical and cytogenetic data were collected retrospectively from cases with t(9;11) identified by conventional cytogenetic studies. The data were used to describe the range of clinical features associated with this abnormality, and to determine which factors may be used to determine prognosis within this group of patients.
Materials and methods
The accrual of cases for this Workshop has been described in detail elsewhere. 10 The collection of data, including the immunophenotype, was used to confirm the diagnosis in as many cases as possible.
Statistical analyses of survival were performed using the BMDP (University of California) suite of computer programs. The generalized Wilcoxon (Peto-Prentice) statistic is given in the Tables here. Three types of time interval were tested: overall survival from diagnosis to death; event-free survival (EFS) from diagnosis to relapse or death, with non-remitting cases being scored as an event on day 1; and EFS with censoring of transplanted patients on the date of transplant. The results of the statistical analyses were generally similar whether survival or event-free survival was used, and so in the rest of this report, only the event-free survival results are described unless otherwise stated. A comparison of the survival of patients who were transplanted against those who had survived at least 3 months but did not have a transplant produced overlapping curves (not shown) and it was concluded that transplant status had rather little effect on outcome in this group of patients; therefore in the analyses reported here, patients were not censored on the date of transplant. The treatment these patients received was varied and so the survival curves shown simply illustrate observations made within this group of patients, which may not be directly comparable with other series of patients. The survival curves were drawn using Statistica.
Cytogenetic data were use to assign the cases to three groups for statistical analyses as follows: (1) with t(9;11) as the sole abnormality; (2) with trisomy 8, whether or not further abnormalities were present; (3) with other additional abnormalities excluding trisomy 8. Five age groups were used in the analyses: infants less than 1 year old, those aged 1 but less than 2 years, ages 2 to 14, 15 to 49, and 50 up.
For multivariate analyses, the Cox proportional hazards model was used, which incorporated a stepwise analysis using the maximum probability likelihood ratio.
Karyotypes for the following six patients, listed in 
Results
There were 125 cases with t(9;11) accepted at this Workshop, sent from 21 centres; 108 had AML, nine had acute lymphoblastic leukemia (ALL), five had myelodysplasia (MDS), two had biphenotypic acute leukemia (BIP), and one had acute undifferentiated leukemia (AUL). Only 10 cases in this series were reported to have secondary disease, nine being AML (one M1, one M2 and seven M5a, median age 44 years, range 24-62) and one being MDS (age 12 years). The cases with secondary disease are considered in more detail in a separate Workshop study report. 15 The t(9;11) was the sole cytogenetic abnormality in 67 cases; in 25 cases trisomy 8 was also present as the only other abnormality, in one case as +i (8) 16 and trisomy 19 in five, this being the only extra abnormality in one case. No extra copies of the der(11) were seen. In seven cases, other chromosomes were involved in a three-way translocation: five of these had AML, three with M5 (Nos 248, 553, 598), one M0 (No. 133) and one with unspecified FAB type (No. 630); one case had ALL (No. 218) and the last had MDS (No. 563). In each case the third chromosome was different or had a different breakpoint; further different involved chromosomes have also been reported. 5, 6 In five cases, one of the two usual derivative chromosomes of the t(9;11) was also involved in some rearrangement with another chromosome (339, 370) or was missing (145, 266) or was unclear (222). Figure 1 shows event-free survival curves for the AML patients comparing t(9;11) as the sole abnormality with trisomy 8 or with another additional abnormality; the presence of trisomy 8 was associated with a more favourable outcome (NS).
The age distribution of all the cases in this series is shown in Figure 2 and event-free survival curves for different age groups of the AML cases are shown in Figure 3 . Many of the AML patients (13.5%) were infants, with almost equal numbers above and below the age of 6 months; 29% were children aged 1-9 years, with a large proportion being aged 1 year; only four were aged 6-9 years. The WBC was known for 98 patients; 34 had counts Ͻ10 × 10 9 /l and 23 had counts Ͼ100 × 10 9 /l ( Figure 4 ). Each higher WBC was associated with a poorer event-free survival (P = 0.00044 in AMLs; P = 0.00091 for all cases).
Of the 105 AML cases with FAB type data, 81 (75%) were M5; 53 were known to be M5a and five were M5b. Eleven cases were M4. It was unfortunate that there were 22 cases of M5 without further assignment into M5a or M5b, since the five cases known to have M5b seemed to have a conspicuously poor outcome, with none surviving beyond 6 months.
The results of univariate analysis of patients with AML are shown in Table 3 . Only two factors were significant, WBC and central nervous system (CNS) involvement. If the series was divided into two groups by age above and below 15 years, then the EFS for the adults was worse than for the children (P = 0.053); comparing the children aged 1 to 14 with the combined infants and adults produced a just significant result (P = 0.032). The results of multivariate analyses are shown in Table 4 . WBC and age were significant prognostic factors in all analyses; CNS involvement was also a significant independent factor, as was karyotype if CNS was excluded from the analysis (because it was not scored for 19 cases). None of the other factors examined was significant. CNS involvement and karyotype may not be entirely independent variables, since no cases in this series with AML, t(9;11) and trisomy 8 had CNS involvement. However, the number of cases with CNS involvement was small: only 11 patients in the whole series were positive out of 103 in which it was reported. Ten patients had AML and one ALL. The EFS of the CNS+ve group was worse than the group of patients in which it had been reported to be absent (P = 0.0017 for AML cases); only one CNS+ve patient survived longer than 2 years, and this was an infant who had a relapse, then a bone marrow transplant 2 years after diagnosis, and was alive 6 years later.
Immunophenotype data for AML cases are listed in Table Table 2 5. The panmyeloid markers CD13 and CD33 were frequently expressed, as were markers for monocytic differentiation, CD11, CD14 and CD15. A stem cell marker, CD34, was expressed in half the cases tested, and 10/26 cases were positive for CD7, usually a T-lineage marker; a further 10 cases expressed some other T-lineage marker, mostly CD4 which is also positive on monocytic cells. Seven of 26 cases tested were positive for a B-lineage marker, mainly CD10 or CD19. Six of the nine patients with ALL were infants (age less than 1 year) and the other three were aged 1, 1 and 12. Seven were female. Only one had a WBC less than 10 × 10 9 /l, and four had a WBC of over 100 × 10 9 /l. The survival of the few t(9;11)+ve patients with ALL in this series appeared to be similar to that of the children with t(9;11) and AML: the event-free survival was not significantly worse (P = 0.564) for ALL than for AML cases aged 0-14 years. There was no follow-up for one patient; three patients were still in first remission at 1, 23 and 53 months; the median event-free survival of the other five was 6.3 months. In looking at the comparison between ALLs and AMLs in more detail, it was observed that infants with ALL fared better and the children appeared to fare worse than the same age group with AML (infants and age 1-14 years, respectively); however the numbers were very small and the differences were not statistically significant. In six cases, t(9;11) was the sole abnormality; the karyotypes of the other three cases are listed in Table 2 .
There were five patients with t(9;11) and MDS in this series and their ages were 1, 1, 3, 12 and 37 years; four were female. S Secondary disease; EFS = event-free survival; +, still in first remission; ++, now in second remission; at dx, short follow-up; OS overall survival; BMT, bone marrow transplant; Auto, autograft; Allo, allograft; yes, transplanted but type unknown; NK, not known.
Table 3
Univariate analyses of event-free survival of patients with t(9;11) and acute myeloid leukemia Although this was a small group, the age distribution was conspicuously less than that of MDS cases in some of the other 11q23 groups, which were predominantly elderly. In three cases, t(9;11) was the sole abnormality. One patient was alive with 8 months follow-up; the overall survival of the others was 1.3, 1.7, 12.3 and 19.2 months. Two cases qualified as biphenotypic; both had cytogenetic abnormalities additional to t(9;11) (see Table 2 ). One case had good morphologic and cytochemical evidence for myeloid differentiation, and could have been included as AML M5a. However, there was expression of surface membrane immunoglobulin, CD24 and CD20, consistent with a mature B phenotype. The other case had features of both AML M7 (expressing platelet markers CD42a and CD61) and T cell lineage, expressing CD3, CD2, CD5 and CD7.
Discussion
Although t(9;11) is the second commonest translocation involving 11q23, there have been relatively few reports devoted to this abnormality. However, it has been previously shown that the prognosis for children 3 and adults 4 with AML 796  Table 4 Multivariate analyses of survival of patients with t(9;11) and acute myeloid leukemia Karyotype groupings: (a) simple t(9;11); (b) with trisomy 8; (c) with other additional abnormalities. Regression covariates entered = age group, sex, WBC group, liver involvement, spleen involvement, lymph node involvement, and CNS involvement or karyotype. Only covariates shown to be significant are listed.
Figure 1
Event-free survival curves for patients with AML and t(9;11), comparing the three karyotype classes: t(9;11) as the sole abnormality; with trisomy 8; with other abnormalities. and t(9;11) is better than for patients with other abnormalities of 11q23, especially with intensive treatment during remission. The series described in this paper shows that it may be possible to identify further subgroups of t(9;11)+ve patients with a relatively better or worse outlook. It is recognised that since these patients came from several centres and did not receive uniform treatment, there should be a measure of caution exercised before attempting to apply the findings of this report prospectively.
There was involvement of MLL in all 40 cases where it had been studied in this series, whether by RT-PCR (reverse transcriptase polymerase chain reaction) (16 cases), FISH (fluorescence in situ hybridization) (11 cases), Southern blotting (nine cases) or a combination of analyses (four cases). This lack of negative results may indicate some selection in the submission of cases for the Workshop, but rather few negative cases have been previously reported, 17, 18 so it seems likely that the incidence of MLL involvement is high in t(9;11) 797 Table 5 Immunophenotypes of patients with t(9;11) and acute myeloid leukemia Positive  Negative   CD13  29  14  CD33  44  6  CD14  12  12  CD15  12  3  CD11a  0  2  CD11b  9  3  CD11c  11 10 18 compared to that in other abnormalities of 11q23, especially del(11)(q). It is therefore difficult to determine whether or not involvement of MLL is a poor prognostic factor in t(9;11), as has been reported for other abnormalities of 11q23 in children. 8 However, it has been reported that in AML M4 and M5, which included a few cases of t(9;11), the presence or absence of MLL rearrangement was not associated with differences in clinical features or treatment outcome. 19 In the series reported here, the outcome for patients with known MLL Figure 2 Bar chart showing the age distribution of all patients with t(9;11) in this report.
involvement was not significantly worse than that of patients in whom it had not been tested (data not shown).
There has been a tendency to move towards using molecular assays to detect common genetic abnormalities, since they have some advantages over conventional cytogenetic analyses in terms of greater sensitivity and lower false-negative rate. The cases studied at this Workshop show that identification of MLL abnormality alone is insufficient without at least identifying the partner chromosome, whether by conventional cytogenetics or by using further FISH/molecular assays. It is also possible that other clinically relevant information can be gained by knowing the full karyotype; the presence of other abnormalities can have an adverse effect on treatment outcome in some instances. 20 In this series the presence of other cytogenetic abnormalities, particularly trisomy 8, was associated with a more favorable outcome, perhaps because of an inverse relationship with the presence of CNS disease. The series of 24 cases reported by Mrozek et al 4 did not find any significant difference in outcome for 11 patients with trisomy 8 (which was the most common additional abnormality, as in this series) compared to 13 without, but they did report a higher remission rate and longer median remission duration for the patients with trisomy 8, inferring that a gain of chromosome 8 or 8q was not an adverse prognostic factor.
There have been very few published data for t(9;11)+ve ALL, and the nine patients in this series constitute a relatively large collection. It has previously been reported that the survival of children with t(9;11)+ve ALL is poor; 7, 8 only one patient in this series has a 4-year event-free survival. It seems that t(9;11)-positive ALL is almost unknown in adults.
AML is generally much rarer than ALL in children and it is
Figure 3
Event-free survival curves for different age groups of patients with AML and t(9;11) in this report.
noteworthy that of the t(9;11)+ve AML patients in this series just over half were aged less than 15 years. It has been reported that the presence of DNA topoisomerase II inhibitors in maternal diet appeared to be associated with 11q23 abnormalities in infant AML; 21 perhaps such an exposure has an effect that continues into childhood.
Previous reports have not given a clear indication of outlook for patients with t(9;11). It has been grouped with complex karyotypes as being associated with poor outcome, 22 and grouped with other MLL+ve 11q23 abnormalities and poor outcome. 8, 23 However, Fenaux et al 24 had no relapses among the patients with t(9;11) in their series, and they suggested that the outlook might be less severe than had been thought, an inference which has been subsequently supported for AML patients, both children 3, 25 and adults. 4 This better prognosis does not appear to apply to children with secondary AML, 2 but we were unable to assess this with our data. In this series, patients aged 1-14 had the best prognosis. The outlook for all MLL+ve infants has been reported to be particularly poor; 8 our data indicate that it may also be poor for patients with t(9;11) aged over 14 years, and even worse for patients aged over 50 years. However, the outlook can be improved for those patients who do achieve remission by ensuring that they are given intensive postinduction therapy. 4 This study of a large series of patients with t(9;11) has shown more clearly the spectrum of disease associations, and the Workshop as a whole demonstrates the striking differences between this group and other groups of translocations involving 11q23. Certain other cytogenetic abnormalities are strongly associated with t(9;11), namely +8, +der (9) , and +19 as shown in this paper and by Mrozek et al. 4 Some published papers have tended to combine all abnormalities of 11q23, when looking at MLL involvement, for example, or survival compared with cytogenetic abnormalities other than 11q23. However, 11q23 or MLL alone should not be presumed to identify a homogenous group; not only does the partner chromosome affect the clinical presentation and treatment outcome, but even within the t(9;11) group other factors, such as age, diagnosis, WBC, CNS involvement, and the presence of other karyotype abnormalities, also have a significant effect. Our data showed that WBC at diagnosis was the most important prognostic factor, followed by age in AML. CNS involvement and/or karyotype class, particularly the presence of trisomy 8, also contributed to prognosis.
Figure 4
Bar chart showing the distribution of white cell counts at diagnosis of all patients with t(9;11) in this report.
